Aliskiren ( DrugBank: Aliskiren )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 4 |
| 167 | Marfan syndrome | 1 |
| 222 | Primary nephrotic syndrome | 3 |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01184599 (ClinicalTrials.gov) | June 2010 | 16/8/2010 | A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy | Glomerulonephritis, IGA;Hypertension | Drug: aliskiren | Kagawa University | NULL | Recruiting | 16 Years | 75 Years | Both | 30 | Phase 4 | Japan | |
| 2 | NCT01129557 (ClinicalTrials.gov) | September 2009 | 21/5/2010 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Terminated | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 3 | NCT00922311 (ClinicalTrials.gov) | July 2009 | 14/6/2009 | Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade | Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study | IgA Nephropathy | Drug: Aliskiren | The University of Hong Kong | Queen Mary Hospital, Hong Kong;United Christian Hospital | Completed | 18 Years | 70 Years | Both | 25 | Phase 4 | China |
| 4 | NCT00870493 (ClinicalTrials.gov) | April 2009 | 26/3/2009 | Aliskiren for Immunoglobulin A (IgA) Nephropathy | The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study | IgA Nephropathy | Drug: Aliskiren;Drug: Placebo | Chinese University of Hong Kong | NULL | Completed | 18 Years | 65 Years | Both | 22 | Phase 3 | Hong Kong |
167. Marfan syndrome
Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01715207 (ClinicalTrials.gov) | June 2010 | 24/10/2012 | Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS | Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol | Marfan Syndrome | Drug: Aliskiren;Drug: Atenolol | Samsung Medical Center | NULL | Completed | 14 Years | 55 Years | All | 30 | Phase 3 | Korea, Republic of |
222. Primary nephrotic syndrome
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04183101 (ClinicalTrials.gov) | October 1, 2020 | 14/11/2019 | Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy | Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy | C3 Glomerulopathy;Membranoproliferative Glomerulonephritis;Complement Abnormality;Dense Deposit Disease;C3 Glomerulonephritis | Drug: Aliskiren;Drug: Enalapril | Region Skane | NULL | Recruiting | 6 Years | N/A | All | 30 | Phase 2 | Sweden |
| 2 | NCT01093781 (ClinicalTrials.gov) | November 2010 | 24/3/2010 | Aliskiren in Patients With Idiopathic Membranous Nephropathy | A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Aliskiren | Mayo Clinic | NULL | Withdrawn | 18 Years | 80 Years | Both | 0 | N/A | United States |
| 3 | NCT01129557 (ClinicalTrials.gov) | September 2009 | 21/5/2010 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Terminated | 18 Years | N/A | All | 46 | Phase 4 | United States |